Edition:
India

Biofrontera AG (BFRA.OQ)

BFRA.OQ on NASDAQ Stock Exchange Capital Market

14.24USD
20 Apr 2018
Change (% chg)

$0.24 (+1.71%)
Prev Close
$14.00
Open
$14.24
Day's High
$14.24
Day's Low
$14.24
Volume
88
Avg. Vol
--
52-wk High
$17.87
52-wk Low
$11.25

Latest Key Developments (Source: Significant Developments)

Biofrontera: 12-Month Follow-Up Results Of Phase III Trial For Daylight PDT
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - BIOFRONTERA AG ::PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA RECEIVES 12-MONTH FOLLOW-UP RESULTS OF THE PHASE III TRIAL FOR DAYLIGHT PDT.OVERALL, COMPARISON OF AMELUZ AND METVIX SHOWS A CLEAR TREND TOWARDS IMPROVED EFFICACY.OVERALL, COMPARISON OF AMELUZ AND METVIX SHOWS LOWER RECURRENCE RATES FOR AMELUZ.  Full Article

Biofrontera Prelim FY 2017 Revenue Expected In Range Of EUR 12.0-12.2 Mln
Monday, 22 Jan 2018 

Jan 22 (Reuters) - BIOFRONTERA AG ::PRELIM UNAUDITED FULL YEAR 2017 REVENUE IS EXPECTED TO BE IN RANGE OF EUR12.0 TO EUR12.2 MILLION.  Full Article

Biofrontera AG Files For U.S. IPO Of Up To $21.6 Million
Saturday, 13 Jan 2018 

Jan 12 (Reuters) - :BIOFRONTERA AG FILES FOR U.S. IPO OF UP TO $21.6 MILLION – SEC FILING.BIOFRONTERA AG - APPLICATION HAS BEEN MADE FOR LISTING OF THE ADS ON THE NASDAQ CAPITAL MARKET UNDER THE SYMBOL “BFRA”.BIOFRONTERA AG SAYS DAWSON JAMES SECURITIES, INC, LAKE STREET CAPITAL MARKETS ARE AMONG UNDERWRITERS TO IPO.  Full Article

Biofrontera Files Investigational New Drug Application
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - BIOFRONTERA AG ::PTA-NEWS: BIOFRONTERA AG: BIOFRONTERA FILES INVESTIGATIONAL NEW DRUG APPLICATION.BIOFRONTERA - ‍FILES INVESTIGATIONAL NEW DRUG APPLICATION WITH U.S. FDA FOR PHASE III TRIAL OF AMELUZ TO TREAT BASAL CELL CARCINOMA​.  Full Article

Biofrontera 9-Mth ‍Net Loss Widens to EUR 14.6 Mln
Monday, 27 Nov 2017 

Nov 27 (Reuters) - BIOFRONTERA AG ::‍REVENUES INCREASED BY 155% TO EUR7.3 MILLION IN 9MTH, COMPARED TO EUR2.9 MILLION IN SAME PERIOD 2016​.‍NET LOSS WAS EUR14.6 MILLION IN FIRST NINE MONTHS 2017, COMPARED TO EUR7.2 MILLION IN SAME PERIOD 2016​.‍ADJUSTED FULL YEAR 2017 REVENUE ESTIMATES TO EUR12 MILLION​.  Full Article

Biofrontera adjusts revenues and earnings forecast for FY 2017
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - BIOFRONTERA AG :PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA ADJUSTS REVENUES AND EARNINGS FORECAST FOR THE FINANCIAL YEAR 2017.‍REVENUES IN Q3 2017 LOWER THAN EXPECTED​.‍NEW REVENUE FORECAST FOR FULL YEAR APPROX. EUR 12 MILLION​.‍TURNAROUND WITH HIGH OCTOBER 2017 REVENUES OF AROUND EUR 1.5 MILLION​.‍REVENUES FOR FIRST NINE MONTHS AT AROUND EUR 7.3 MILLION​.‍ADJUSTS ITS FY FORECAST FOR CONSOLIDATED NET RESULT TO EUR -18 MILLION​.  Full Article

Biofrontera: CMS issues new reimbursement codes for Ameluz
Friday, 10 Nov 2017 

Nov 10 (Reuters) - BIOFRONTERA AG ::PTA-NEWS: BIOFRONTERA AG: CMS ISSUES NEW REIMBURSEMENT CODES FOR AMELUZ® AND FOR PHOTODYNAMIC THERAPY.  Full Article

Biofrontera achieves strong U.S. sales performance of Ameluz in first year
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - BIOFRONTERA AG :PTA-NEWS: BIOFRONTERA AG: BIOFRONTERA ACHIEVES STRONG U.S. SALES PERFORMANCE OF AMELUZ® IN FIRST YEAR OF COMMERCIALIZATION.‍AMELUZ HAS BEEN ADOPTED BY 425 U.S. CUSTOMERS, GENERATING SALES OF APPROXIMATELY USD5 MILLION TO DATE​.  Full Article

Biofrontera: Ameluz and BF-RhodoLED listed on U.S. VA Federal Supply Schedule
Monday, 9 Oct 2017 

Oct 9 (Reuters) - BIOFRONTERA AG :PTA-NEWS: BIOFRONTERA AG: BIOFRONTERA'S AMELUZ® AND BF-RHODOLED® LISTED ON THE U.S. VA FEDERAL SUPPLY SCHEDULE.  Full Article

Biofrontera H1 sales up 9 pct at 1.709 million euros
Wednesday, 31 Aug 2016 

Biofrontera AG : Sales increased 9 pct to 1.709 million euros ($1.90 million)in H1 2016 compared to 1.568 million euros in H1 2015 . Net income loss was 3.472 million euros in H1 2016 compared to 7.323 million euros in H1 2015 .Cash on balance sheet was 10.2 million euros as of June 30.  Full Article

BRIEF-Biofrontera: European Commission Approves Use Of Ameluz In Combination With Daylight Photodynamic Therapy

* PTA-ADHOC: BIOFRONTERA AG: EUROPEAN COMMISSION APPROVES USE OF AMELUZ IN COMBINATION WITH DAYLIGHT PHOTODYNAMIC THERAPY Source text for Eikon: Further company coverage: (Gdynia Newsroom)